Denali Therapeutics 향후 성장

Future 기준 점검 2/6

Denali Therapeutics (는) 각각 연간 31.6% 및 50.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 33.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -79.7% 로 예상됩니다.

핵심 정보

31.6%

이익 성장률

33.77%

EPS 성장률

Biotechs 이익 성장	23.2%
매출 성장률	50.5%
향후 자기자본이익률	-79.74%
애널리스트 커버리지	Good
마지막 업데이트	30 Dec 2025

최근 향후 성장 업데이트

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06

이익 및 매출 성장 예측

NasdaqGS:DNLI - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	492	-223	-9	-238	11
12/31/2027	161	-487	-374	-341	14
12/31/2026	61	-518	-456	-280	17
12/31/2025	3	-515	-485	-389	15
9/30/2025	N/A	-499	-411	-398	N/A
6/30/2025	N/A	-479	-368	-350	N/A
3/31/2025	N/A	-454	-384	-366	N/A
12/31/2024	N/A	-423	-364	-348	N/A
9/30/2024	N/A	-427	-376	-363	N/A
6/30/2024	1	-420	-402	-391	N/A
3/31/2024	295	-137	-425	-413	N/A
12/31/2023	331	-145	-371	-358	N/A
9/30/2023	341	-124	-348	-332	N/A
6/30/2023	343	-128	-321	-302	N/A
3/31/2023	101	-371	-248	-231	N/A
12/31/2022	108	-326	-263	-245	N/A
9/30/2022	111	-303	-254	-238	N/A
6/30/2022	112	-284	-234	-222	N/A
3/31/2022	83	-286	-243	-233	N/A
12/31/2021	49	-291	-220	-211	N/A
9/30/2021	353	30	361	368	N/A
6/30/2021	357	56	404	410	N/A
3/31/2021	340	58	415	420	N/A
12/31/2020	336	71	413	416	N/A
9/30/2020	24	-228	-150	-145	N/A
6/30/2020	28	-216	-183	-176	N/A
3/31/2020	26	-215	-193	-176	N/A
12/31/2019	27	-198	-169	-152	N/A
9/30/2019	148	-66	-27	-11	N/A
6/30/2019	135	-55	N/A	-15	N/A
3/31/2019	133	-52	N/A	-14	N/A
12/31/2018	129	-36	N/A	50	N/A
9/30/2018	3	-137	N/A	-61	N/A
6/30/2018	2	-123	N/A	-49	N/A
3/31/2018	1	-91	N/A	-24	N/A
12/31/2017	N/A	-88	N/A	-77	N/A
9/30/2017	N/A	-85	N/A	-77	N/A
6/30/2017	N/A	-93	N/A	-76	N/A
3/31/2017	N/A	-90	N/A	-75	N/A
12/31/2016	N/A	-87	N/A	-72	N/A

애널리스트 향후 성장 전망

수입 대 저축률: DNLI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: DNLI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: DNLI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: DNLI 의 수익(연간 50.5%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: DNLI 의 수익(연간 50.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: DNLI는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/02 14:48
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Denali Therapeutics Inc.는 30명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
null null	Baird
Joel Beatty	Baird
Charles Moore	Baird

Denali Therapeutics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates decrease by 71%

Consensus revenue estimates fall by 26%

Price target decreased by 11% to US$32.56

Consensus revenue estimates decrease by 48%, EPS upgraded

Price target decreased by 7.3% to US$39.67

Consensus revenue estimates fall by 49%

Recent updates

Denali Therapeutics Inc. Announces Publication of Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Denali Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Denali Therapeutics Inc. Announces Board and Executive Changes

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Consensus revenue estimates decrease by 71%

Co-Founder notifies of intention to sell stock

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

New major risk - Revenue and earnings growth

Denali Therapeutics Inc. Elects Julian Baker as Class II Director

Insufficient new directors

Consensus revenue estimates fall by 26%

Price target decreased by 11% to US$32.56

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Denali Therapeutics Inc., Annual General Meeting, Jun 03, 2025

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through Start Program

New minor risk - Share price stability

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Consensus revenue estimates decrease by 48%, EPS upgraded

Denali Therapeutics Inc. has withdrawn its Follow-on Equity Offering in the amount of $400 million.

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Co-Founder recently sold US$751k worth of stock

Co-Founder notifies of intention to sell stock

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Price target decreased by 7.3% to US$39.67

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 49%

New major risk - Revenue size

Co-Founder notifies of intention to sell stock

Director notifies of intention to sell stock

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

New minor risk - Insider selling

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 14%

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Consensus revenue estimates decrease by 45%, EPS upgraded

First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023)

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Now 21% undervalued

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Consensus revenue estimates fall by 29%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Consensus revenue estimates decrease by 49%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium

Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium

Insufficient new directors

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Co-Founder recently sold US$340k worth of stock

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Co-Founder notifies of intention to sell stock

Price target decreased by 7.1% to US$48.53